{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:51Z","timestamp":1787009031056,"version":"build-2736575974"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","award":["1489"],"award-info":[{"award-number":["1489"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","award":["1490"],"award-info":[{"award-number":["1490"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Two Phase 3, randomized, double-blind, active-controlled studies of initial HIV-1 treatment demonstrated that bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) was non-inferior to dolutegravir\/abacavir\/lamivudine (DTG\/ABC\/3TC; Study 1489) or to DTG+F\/TAF (Study 1490) through 144\u2009weeks. In both studies, there was no emergent resistance to study drugs. Here, the 3\u2009year resistance analysis and impact of baseline resistance substitutions on treatment response are described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. Retrospective baseline next generation sequencing of protease, RT and integrase (IN) was analysed at a \u2265\u200a15% cutoff. Resistance analyses were performed on participants with confirmed viral rebound of HIV-1 RNA \u2265200 copies\/mL through Week 144 or last visit who did not resuppress to &amp;lt;50 copies\/mL while on study drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Transmitted primary drug resistance substitutions were present in the following proportions of participants: integrase strand transfer inhibitor (INSTI) resistance (-R) in 1.3% (17\/1270) of participants; NRTI-R in 2.7% (35\/1274); NNRTI-R in 14.1% (179\/1274); and PI-R in 3.5% (44\/1274). These pre-existing resistance substitutions not associated with study drug did not affect treatment outcomes. One participant in the B\/F\/TAF group had pre-existing bictegravir and dolutegravir resistance substitutions (Q148H+G140S in integrase) at baseline and suppressed and maintained HIV-1 RNA &amp;lt;50 copies\/mL through Week 144. In total, 21 participants qualified for resistance testing [1.3% (8\/634) B\/F\/TAF; 1.9% (6\/315) DTG\/ABC\/3TC; 2.2% (7\/325) DTG+F\/TAF]; none had emergent resistance to study drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with B\/F\/TAF, DTG\/ABC\/3TC, or DTG+F\/TAF achieved high, durable rates of virological suppression in HIV-1 treatment-naive participants. The presence of pre-existing resistance substitutions did not affect treatment outcomes, and there was no treatment-emergent resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkab115","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T08:09:42Z","timestamp":1616573382000},"page":"2153-2157","source":"Crossref","is-referenced-by-count":13,"title":["Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV-1 treatment-naive participants"],"prefix":"10.1093","volume":"76","author":[{"given":"Rima K","family":"Acosta","sequence":"first","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Q","family":"Chen","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Huang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Brainard","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E","family":"Collins","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L","family":"White","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"2021071609140893900_dkab115-B1","year":"2019"},{"key":"2021071609140893900_dkab115-B2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2021071609140893900_dkab115-B3","year":"2019"},{"key":"2021071609140893900_dkab115-B4","year":"2019"},{"key":"2021071609140893900_dkab115-B5","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609140893900_dkab115-B6","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials [Supplementary Appendix]","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"2021071609140893900_dkab115-B7","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2021071609140893900_dkab115-B8","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2021071609140893900_dkab115-B9","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/jac\/dkv149","article-title":"Analysis of early resistance development at the first failure timepoint in elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate-treated patients","volume":"70","author":"White","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021071609140893900_dkab115-B10","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1128\/AAC.02533-18","article-title":"Resistance analysis of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks","volume":"63","author":"Acosta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021071609140893900_dkab115-B11","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Topics Antiviral Med"},{"key":"2021071609140893900_dkab115-B12","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART","volume":"10","author":"Shafer","year":"2008","journal-title":"AIDS Rev"},{"key":"2021071609140893900_dkab115-B13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect Genet Evol"},{"key":"2021071609140893900_dkab115-B14","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1097\/QAD.0000000000000494","article-title":"Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis","volume":"28","author":"Pham","year":"2014","journal-title":"AIDS"},{"key":"2021071609140893900_dkab115-B15","year":"2017"},{"key":"2021071609140893900_dkab115-B16","author":"Robineau"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/8\/2153\/39065391\/dkab115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/8\/2153\/39065391\/dkab115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:18:02Z","timestamp":1626412682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/8\/2153\/6242736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4,21]]},"published-print":{"date-parts":[[2021,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab115","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,4,21]]}}}